Home- Conferences
- Workshops & Training
- Program
- Overview
- *Innovation Cafe
- Drug Safety
- Confidence in Safety
- Speakers
- Averback, J
- Clark, J
- Cook, J
- Corderoy, M
- Elkin, P
- Fontaine, L
- Hardy, B
- Hongsermeier, T
- Kahn, S
- Neumann, E
- Newman, V
- Odle, G
- Shakir, S
- Spitzner, J
- Starry, S
- Torr-Brown, S
- Weidner, D
- Weintraub, H
- Abstracts
- Overview
- Program Outline
- Counterfeit Drugs
- Valuation & Auditing
- Drug Discovery Innovation
- Drug Development
- Complex Systems & Org. Development
- Semantic Web
- R&D Knowledge Management
- Molecular Medicine
- Nanobiotech
- Personalised Medicine
- Research
- Exhibition
- Registration
- About
- Overview
- Contact
- Support
- Schedule
|
|
|
|
|
|
|
|
|
| Eric Neumann, Global Head of Knowledge Management, Sanofi-Aventis |
|
Eric Neumann is global head of the Knowledge Management for Aventis Drug Innovation and Approval. Dr. Neumann is an expert in knowledge-based methods of working in the pharmaceutical industry, which has been his interest for the past 12 years. Prior to joining Aventis, Dr. Neumann was at Beyond Genomics, a biopharmaceutical company based in Waltham, Massachusetts, which was founded to discover and develop new drugs by exploiting unique technologies and the knowledge generated from the "-omics" revolution. At Beyond Genomics, Dr. Neumann held the position of VP of Bioinfomatics and Knowledge Research, in which position he led collaborative deals with such pharmaceutical companies as Novartis and GlaxoSmithKline. He is also the co-founder and Scientific Advisor for Genstruct, a Cambridge, Massachusetts-based company that applies a unique Knowledge Assembly and Molecular Epistemics approach to reveal disease mechanisms, optimal validation strategies, mechanisms of action and pre-clinical development strategies.
Prior to Beyond Genomics, Eric Neumann was VP of Life Science and Informatics at 3rd Millennium, a developer of custom software systems for biotech and pharmaceutical R&D, which is also located in Waltham, Massachusetts. He has also held positions at NetGenics (now LION), a company that built integrated informatics solutions, and Bolt, Beranek & Newman, a renowned R&D company that provides advanced research and custom, research-based solutions for customers in the private and public sector.
Dr. Neumann completed his bachelor's degree in Life Science at the Massachusetts Institute of Technology, in Cambridge, Massachusetts. In 1989, he was awarded a Ph.D. in pharmacology, neurobiology and developmental genetics at Case Western Reserve University, in Cleveland, Ohio. Dr. Neumann is driven by the belief that there is an enormous opportunity to improve drug discovery processes by encouraging the exchange of information.
|
|
|
|
|
|
|
|
|
|
|
